A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Kantarjian HM, Gattermann N, Hochhaus A, Larson R, Rafferty T, Weitzman A, Haque A, Giles F, O'Brien SG, le Coutre P

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 48th Annual Meeting of the Annual Society of Hematology

Year of Conference: 2006

Pages: 615A-615A

Publisher: Blood: American Society of Hematology

Notes: Abstract 2169 Poster Board Session 347-II

Library holdings: Search Newcastle University Library for this item

ISBN:

ePrints